Molecular genetic positioning of small intestine and papilla of Vater carcinomas including clinicopathological classification.
Humans
Prognosis
Ampulla of Vater
/ pathology
Pancreatic Neoplasms
/ pathology
Carcinoma, Pancreatic Ductal
/ pathology
Adenocarcinoma
/ pathology
Cholangiocarcinoma
/ pathology
Intestine, Small
/ pathology
Bile Duct Neoplasms
/ pathology
Bile Ducts, Intrahepatic
/ pathology
Molecular Biology
Pancreatic Neoplasms
gene expression
molecular genetics
pancreatic invasion
papilla of Vater carcinoma
small intestine carcinoma
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
revised:
13
01
2023
received:
29
11
2022
accepted:
19
03
2023
medline:
7
6
2023
pubmed:
1
4
2023
entrez:
31
3
2023
Statut:
ppublish
Résumé
Small intestine carcinoma (SIC) cases in Japan have recently been treated with chemotherapy according to colorectal carcinoma classification, while papilla of Vater carcinoma (PVC) cases according to cholangiocarcinoma (CHC) classification. However, few research reports support the molecular genetic validity of these therapeutic choices. Here, we investigated the clinicopathological and molecular genetic factors of SIC and PVC. We used the data from the Japanese version of The Cancer Genome Atlas. Additionally, molecular genetic data on gastric adenocarcinoma (GAD), colorectal adenocarcinoma (CRAD), pancreatic ductal adenocarcinoma (PDAC), and CHC were also referred to. This study consisted of tumor samples from 12 patients of SIC and three patients of PVC treated from January 2014 to March 2019. Among them, six patients had pancreatic invasion. t-Distributed stochastic neighbor embedding analysis showed that the gene expression pattern of SIC was similar not only to those of GAD and CRAD, but also to that of PDAC in the pancreatic invasion patients. In addition, PVC resembled the GAD, CRAD, and PDAC, rather than the CHC. The molecular genetic characteristics of the six patients with pancreatic invasion were: one had high microsatellite instability, two had a TP53 driver mutation, and three had tumor mutation burden values <1 mutation/Mb with no driver mutation. In this study, the extensive gene expression profiling of organ carcinomas newly suggests that SIC or PVC may resemble GAD, CRAD, and PDAC. In addition, the data demonstrate that pancreatic invasive patients may be classified into several subtypes using molecular genetic factors.
Sections du résumé
BACKGROUND
Small intestine carcinoma (SIC) cases in Japan have recently been treated with chemotherapy according to colorectal carcinoma classification, while papilla of Vater carcinoma (PVC) cases according to cholangiocarcinoma (CHC) classification. However, few research reports support the molecular genetic validity of these therapeutic choices.
PATIENTS AND METHODS
Here, we investigated the clinicopathological and molecular genetic factors of SIC and PVC. We used the data from the Japanese version of The Cancer Genome Atlas. Additionally, molecular genetic data on gastric adenocarcinoma (GAD), colorectal adenocarcinoma (CRAD), pancreatic ductal adenocarcinoma (PDAC), and CHC were also referred to.
RESULTS
This study consisted of tumor samples from 12 patients of SIC and three patients of PVC treated from January 2014 to March 2019. Among them, six patients had pancreatic invasion. t-Distributed stochastic neighbor embedding analysis showed that the gene expression pattern of SIC was similar not only to those of GAD and CRAD, but also to that of PDAC in the pancreatic invasion patients. In addition, PVC resembled the GAD, CRAD, and PDAC, rather than the CHC. The molecular genetic characteristics of the six patients with pancreatic invasion were: one had high microsatellite instability, two had a TP53 driver mutation, and three had tumor mutation burden values <1 mutation/Mb with no driver mutation.
CONCLUSIONS
In this study, the extensive gene expression profiling of organ carcinomas newly suggests that SIC or PVC may resemble GAD, CRAD, and PDAC. In addition, the data demonstrate that pancreatic invasive patients may be classified into several subtypes using molecular genetic factors.
Identifiants
pubmed: 36999887
doi: 10.1002/cam4.5877
pmc: PMC10242328
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
11491-11502Informations de copyright
© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Sci Rep. 2017 Apr 4;7(1):641
pubmed: 28377632
Ann Oncol. 2019 Jul 1;30(7):1096-1103
pubmed: 31038663
Am J Surg Pathol. 2014 Nov;38(11):1484-93
pubmed: 25310836
Biomed Res. 2016;37(6):359-366
pubmed: 28003583
Nat Med. 2017 Jun;23(6):703-713
pubmed: 28481359
Ann Surg. 1995 Nov;222(5):632-7
pubmed: 7487210
Biomed Res. 2016;37(6):367-379
pubmed: 28003584
Cell Rep. 2016 Feb 2;14(4):907-919
pubmed: 26804919
Cancer Med. 2023 May;12(10):11491-11502
pubmed: 36999887
Cancer Cell. 2016 Feb 8;29(2):229-40
pubmed: 26806338
N Engl J Med. 2010 Apr 8;362(14):1273-81
pubmed: 20375404
Histopathology. 2020 Jan;76(2):182-188
pubmed: 31433515
Nat Commun. 2022 Jul 23;13(1):4264
pubmed: 35871175
Cancer. 2016 Jun 1;122(11):1689-96
pubmed: 26998897
Br J Cancer. 2013 Dec 10;109(12):3057-66
pubmed: 24196786
Nature. 2014 Sep 11;513(7517):202-9
pubmed: 25079317
Int J Clin Oncol. 2021 Aug;26(8):1353-1419
pubmed: 34185173
Biomed Res. 2014;35(6):407-12
pubmed: 25743347
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Clin Cancer Res. 2019 Jan 15;25(2):641-651
pubmed: 30352910
BMC Cancer. 2022 Jul 2;22(1):723
pubmed: 35778698
JAMA Oncol. 2017 Nov 01;3(11):1546-1553
pubmed: 28617917
J Hepatobiliary Pancreat Sci. 2021 Jan;28(1):26-54
pubmed: 33259690
Cell. 2022 Feb 3;185(3):563-575.e11
pubmed: 35120664
Cancer Cell. 2017 Aug 14;32(2):185-203.e13
pubmed: 28810144
Nature. 2012 Jul 18;487(7407):330-7
pubmed: 22810696
Lancet Oncol. 2017 Sep;18(9):1182-1191
pubmed: 28734759
Cancer Sci. 2020 Feb;111(2):687-699
pubmed: 31863614
PLoS Genet. 2018 Mar 9;14(3):e1007200
pubmed: 29522538
Lancet Oncol. 2021 May;22(5):690-701
pubmed: 33798493
Bioinformatics. 2014 Apr 1;30(7):1015-6
pubmed: 24371154
Ann Surg Oncol. 2020 Oct;27(11):4553-4560
pubmed: 32367502
Sci Rep. 2018 Jun 7;8(1):8700
pubmed: 29880869
Gastroenterol Clin North Am. 2016 Sep;45(3):447-57
pubmed: 27546842
Cancer Sci. 2020 Oct;111(10):3893-3901
pubmed: 32662546
Clin Cancer Res. 2019 Feb 1;25(3):1063-1069
pubmed: 30045933